Vis enkel innførsel

dc.contributor.authorSchou, Morten Brix
dc.contributor.authorSæther, Sverre Georg
dc.contributor.authorDrange, Ole Kristian
dc.contributor.authorKrane-Gartiser, Karoline
dc.contributor.authorReitan, Solveig Merete Klæbo
dc.contributor.authorVaaler, Arne
dc.contributor.authorKondziella, Daniel
dc.date.accessioned2018-12-10T11:36:57Z
dc.date.available2018-12-10T11:36:57Z
dc.date.created2018-11-21T10:35:33Z
dc.date.issued2018
dc.identifier.citationBMC Neuroscience. 2018, 19:68 1-8.nb_NO
dc.identifier.issn1471-2202
dc.identifier.urihttp://hdl.handle.net/11250/2576913
dc.description.abstractBackground The clinical significance of anti-neuronal antibodies in patients with psychiatric disorders, but without encephalitis, remains unknown. In patients admitted to acute psychiatric inpatient care we aimed to identify clinical features distinguishing anti-neuronal antibody positive patients from matched controls. Results Patients who were serum-positive to N-methyl d-aspartate receptor (NMDAR) (n = 21), contactin-associated protein 2 (CASPR2) (n = 14) and/or glutamic acid decarboxylase 65 (GAD65) (n = 9) antibodies (cases) were age and sex matched (1:2) with serum-negative patients from the same cohort (controls). The prevalence and severity of psychiatric symptoms frequently encountered in NMDAR, CASPR2 and GAD65 antibody associated disorders were compared in cases and controls. NMDAR, CASPR2 and GAD65 antibody positive patients did not differ in their clinical presentation from matched serum negative controls. Conclusion In this cohort, patients with and without NMDAR, CASPR2 and GAD65 antibodies admitted to acute psychiatric inpatient care had similar psychiatric phenotypes. This does not exclude their clinical relevance in subgroups of patients, and studies further investigating the clinical significance of anti-neuronal antibodies in patients with psychiatric symptomatology are needed.nb_NO
dc.language.isoengnb_NO
dc.publisherBMC (part of Springer Nature)nb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe significance of anti-neuronal antibodies for acute psychiatric disorders: a retrospective case-controlled studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-8nb_NO
dc.source.volume19:68nb_NO
dc.source.journalBMC Neurosciencenb_NO
dc.identifier.doi10.1186/s12868-018-0471-7
dc.identifier.cristin1633118
dc.description.localcode© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)nb_NO
cristin.unitcode194,65,35,0
cristin.unitnameInstitutt for psykisk helse
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal